Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Buspirone is a non-benzodiazepine anxiolytic drug that belongs to the chemical class of azaspirones. It is a highly specific compound that selectively acts as a 5-hydroxytryptamine (5-HT1) receptor agonist, providing anxiolytic effects without the sedative, muscle relaxant, or anticonvulsant properties associated with benzodiazepines.

36505-84-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 36505-84-7 Structure
  • Basic information

    1. Product Name: Buspirone
    2. Synonyms: 8-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-8-AZASPIRO[4,5]DECANE-7,9-DIONE;8-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-8-AZASPIRO[4,5]DECANE-7,9-DIONE HYDROCHLORIDE;5)decane-7,9-dione,8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)-8-azaspiro(;8-(4-(4-(2-pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione;BUSPIRONE,USP;Buspirone (base and/or unspecified salts);BUPROPIONHCL;Ansiced:Axoren
    3. CAS NO:36505-84-7
    4. Molecular Formula: C21H31N5O2
    5. Molecular Weight: 385.5
    6. EINECS: 253-072-2
    7. Product Categories: N/A
    8. Mol File: 36505-84-7.mol
    9. Article Data: 13
  • Chemical Properties

    1. Melting Point: 2-8°C
    2. Boiling Point: 511.93°C (rough estimate)
    3. Flash Point: 325.1 °C
    4. Appearance: white
    5. Density: 1.1527 (rough estimate)
    6. Refractive Index: 1.7600 (estimate)
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: pKa 7.60±0.01(H2O t=25.0 I=0.1(NaCl)) (Uncertain)
    10. CAS DataBase Reference: Buspirone(CAS DataBase Reference)
    11. NIST Chemistry Reference: Buspirone(36505-84-7)
    12. EPA Substance Registry System: Buspirone(36505-84-7)
  • Safety Data

    1. Hazard Codes: T
    2. Statements: 25
    3. Safety Statements: 45
    4. RIDADR: UN 2811 6.1/PG 3
    5. WGK Germany: 3
    6. RTECS: CL9915000
    7. HazardClass: N/A
    8. PackingGroup: N/A
    9. Hazardous Substances Data: 36505-84-7(Hazardous Substances Data)

36505-84-7 Usage

Uses

Used in Pharmaceutical Industry:
Buspirone is used as a tranquilizer for the treatment of mild anxiety disorders. It is effective in reducing anxiety symptoms while avoiding the side effects commonly associated with benzodiazepines, such as sedation and dependence.
Used in Research and Development:
As a highly specific anxiolytic, Buspirone is used in research to study the role of 5-HT1 receptors in anxiety and other related disorders. This helps in the development of new drugs and therapies targeting these receptors for the treatment of anxiety and other mental health conditions.
Used in Impurity Testing:
5-Chloro Buspirone is an impurity of Buspirone Hydrochloride, a non-benzodiazepine anxiolytic. It is important to monitor and control the levels of this impurity in the final drug product to ensure safety, efficacy, and quality.

Biological Functions

Buspirone (BuSpar) is the first example of a class of anxiolytic agents that can relieve some symptoms of anxiety in doses that do not cause sedation. Buspirone is structurally unrelated to existing psychotropic drugs.

Mechanism of action

Although buspirone has been shown to interact with a number of neurotransmitter systems in the brain, it appears that its clinically relevant effects are mediated through interactions at the serotonin (5-hydroxytryptamine, 5-HT) 5-HT1A receptor, where it acts as a partial agonist.

Pharmacology

Buspirone is as effective as the benzodiazepines in the treatment of general anxiety. However, the full anxiolytic effect of buspirone takes several weeks to develop, whereas the anxiolytic effect of the benzodiazepines is maximal after a few days of therapy. In therapeutic doses, buspirone has little or no sedative effect and lacks the muscle relaxant and anticonvulsant properties of the benzodiazepines. In addition, buspirone does not potentiate the central nervous system depression caused by sedative–hypnotic drugs or by alcohol, and it does not prevent the symptoms associated with benzodiazepine withdrawal.

Clinical Use

Buspirone is effective in general anxiety and in anxiety with depression.

Side effects

Like the benzodiazepines, buspirone appears to be safe even when given in very high doses. The most common side effects are dizziness, light-headedness, and headache. Abuse, dependence, and withdrawal have not been reported, and buspirone administration does not produce any cross-tolerance to the benzodiazepines. Buspirone has been reported to increase blood pressure in patients taking monoamine oxidase inhibitors, and it may increase plasma levels of haloperidol if coadministered with that agent.

Synthesis

Buspirone, 8-[4-[4-(2-pyrimidyl)-1-piperazinyl]butyl]-8-azaspiro [4,5] decan-7,9-dione (5.2.6), is synthesized by the reaction of 1-(2-pyrimidyl)-4- (4-aminobutyl)piperazine (5.2.4) with 8-oxaspiro[4,5]decan-7,9-dione (5.2.5). In turn, 1- (2-pyrimidyl)-4-(4-aminobutyl)piperazine (5.2.4) is synthesized by the reaction of 1-(2-pyrimidyl)piperazine with 4-chlorobutyronitrile, giving 4-(2-pyrimidyl)-1-(3- cyanopropyl)piperazine (5.2.3), which is hydrogenated with Raney nickel into buspirone (5.2.4) [51–55].

Metabolism

Buspirone is well absorbed from the gastrointestinal tract, and peak blood levels are achieved in 1 to 1.5 hours; the drug is more than 95% bound to plasma proteins. Buspirone is extensively metabolized, with less than 1% of the parent drug excreted into the urine unchanged. At least one of the metabolic products of buspirone is biologically active. The parent drug has an elimination half-life of 4 to 6 hours.

Check Digit Verification of cas no

The CAS Registry Mumber 36505-84-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,5,0 and 5 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 36505-84:
(7*3)+(6*6)+(5*5)+(4*0)+(3*5)+(2*8)+(1*4)=117
117 % 10 = 7
So 36505-84-7 is a valid CAS Registry Number.
InChI:InChI=1/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2

36505-84-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name Buspirone

1.2 Other means of identification

Product number -
Other names Bespar

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:36505-84-7 SDS

36505-84-7Synthetic route

1,4-dibromo-butane
110-52-1

1,4-dibromo-butane

N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

tetramethylene glutarimide
1075-89-4

tetramethylene glutarimide

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With potassium carbonate; benzyltriethylammonium bromide Product distribution; 1.) xylene, reflux, 3 h, 2.) reflux, 5 h; other imides and catalysts, variation of reaction time, also in toluene; also 1-(2-quinolinyl)piperazine;97%
With potassium carbonate; benzyltriethylammonium bromide 1.) xylene, reflux, 3 h, 2.) reflux, 5 h; Yield given. Multistep reaction;
2-chloropyrimidine
1722-12-9

2-chloropyrimidine

8-(4-(piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione
80827-59-4

8-(4-(piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With C48H55ClN2Pd; sodium t-butanolate In 1,2-dimethoxyethane at 20℃; for 16h; Inert atmosphere; Sealed tube;90%
3,3-tetramethylene glutaric anhydride
5662-95-3

3,3-tetramethylene glutaric anhydride

1-(pyrimidin-2-yl)-4-(4-aminobutyl)piperazine
33386-20-8

1-(pyrimidin-2-yl)-4-(4-aminobutyl)piperazine

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
In toluene for 10h; Heating;78%
8-(4-hydroxybutyl)-8-azaspiro[4.5]decane-7,9-dione
21098-10-2

8-(4-hydroxybutyl)-8-azaspiro[4.5]decane-7,9-dione

N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With [RhCl2(p-cymene)]2; bis[2-(diphenylphosphino)phenyl] ether In tetrahydrofuran at 250℃; under 37503.8 Torr; Flow reactor;76%
N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

8-(4-bromobutyl)-8-azaspiro[4.5]decane-7,9-dione
80827-62-9

8-(4-bromobutyl)-8-azaspiro[4.5]decane-7,9-dione

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 12h; Heating;71.4%
With potassium carbonate In N,N-dimethyl-formamide at 80℃;
8-<4-(4-pyrimidin-2-yl-piperazin-1-yl)but-2-enyl>-8-aza-spiro<4.5>decane-7,9-dione
118286-98-9

8-<4-(4-pyrimidin-2-yl-piperazin-1-yl)but-2-enyl>-8-aza-spiro<4.5>decane-7,9-dione

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In ethyl acetate70%
8-(4-(piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione
80827-59-4

8-(4-(piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione

2-fluoropyrimidine
31575-35-6

2-fluoropyrimidine

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With potassium hydroxide; hydroxypropyl methylcellulose In water at 20℃;62%
tetramethylene glutarimide
1075-89-4

tetramethylene glutarimide

8-(2-Pyrimidinyl)-8-aza-5-azoniaspiro[4.5]decane Bromide
81461-73-6

8-(2-Pyrimidinyl)-8-aza-5-azoniaspiro[4.5]decane Bromide

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With potassium carbonate; 18-crown-6 ether In xylene for 6h; Heating;
With sodium hydroxide; potassium carbonate In N-methyl-acetamide; hydrogenchloride; water
8-<4-<4-(2-Pyrimidinyl)-1-piperazinyl>-2-butynyl>-8-azaspiro<4.5>decane-7,9-dione
118286-97-8

8-<4-<4-(2-Pyrimidinyl)-1-piperazinyl>-2-butynyl>-8-azaspiro<4.5>decane-7,9-dione

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In tetrahydrofuran for 0.833333h; Ambient temperature; Yield given;
N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 50 percent / Pd(PPh3)4 / tetrahydrofuran
2: 70 percent / Pd(PPh3)4 / tetrahydrofuran; dimethylsulfoxide
3: 70 percent / H2 / Pd/C / ethyl acetate
View Scheme
Multi-step reaction with 3 steps
1: 80 percent / Pd(PPh3)4 / tetrahydrofuran
2: 70 percent / Pd(PPh3)4 / tetrahydrofuran; dimethylsulfoxide
3: 70 percent / H2 / Pd/C / ethyl acetate
View Scheme
Multi-step reaction with 3 steps
1: 56 percent / Pd(PPh3)4 / tetrahydrofuran
2: 70 percent / Pd(PPh3)4 / tetrahydrofuran; dimethylsulfoxide
3: 70 percent / H2 / Pd/C / ethyl acetate
View Scheme
tetramethylene glutarimide
1075-89-4

tetramethylene glutarimide

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 70 percent / Pd(PPh3)4 / tetrahydrofuran; dimethylsulfoxide
2: 70 percent / H2 / Pd/C / ethyl acetate
View Scheme
Multi-step reaction with 3 steps
1: 100 percent / K2CO3 / acetone / Heating
2: 65 percent / CuCl2 * 2 H2O / dioxane; H2O / 1.5 h / 70 - 80 °C
3: H2 / 10percent Pd/C / tetrahydrofuran / 0.83 h / Ambient temperature
View Scheme
4-(4-pyrimidin-2-yl-piperazin-1-yl)but-2-enyl acetate

4-(4-pyrimidin-2-yl-piperazin-1-yl)but-2-enyl acetate

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 70 percent / Pd(PPh3)4 / tetrahydrofuran; dimethylsulfoxide
2: 70 percent / H2 / Pd/C / ethyl acetate
View Scheme
N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

methyl halide

methyl halide

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 65 percent / CuCl2 * 2 H2O / dioxane; H2O / 1.5 h / 70 - 80 °C
2: H2 / 10percent Pd/C / tetrahydrofuran / 0.83 h / Ambient temperature
View Scheme
3,3-tetramethylene glutaric anhydride
5662-95-3

3,3-tetramethylene glutaric anhydride

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 92 percent / 7percent aq. NH3 / tetrahydrofuran / 190 °C
2: 100 percent / K2CO3 / acetone / Heating
3: 65 percent / CuCl2 * 2 H2O / dioxane; H2O / 1.5 h / 70 - 80 °C
4: H2 / 10percent Pd/C / tetrahydrofuran / 0.83 h / Ambient temperature
View Scheme
8-Propargyl-8-azaspiro<4.5>decane-7,9-dione
25032-23-9

8-Propargyl-8-azaspiro<4.5>decane-7,9-dione

BUSPIRONE
36505-84-7

BUSPIRONE

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 65 percent / CuCl2 * 2 H2O / dioxane; H2O / 1.5 h / 70 - 80 °C
2: H2 / 10percent Pd/C / tetrahydrofuran / 0.83 h / Ambient temperature
View Scheme
BUSPIRONE
36505-84-7

BUSPIRONE

C21H29(2)H2N5O2

C21H29(2)H2N5O2

Conditions
ConditionsYield
With [(N,N′-bis(2,6-diisopropylphenyl)-2,3-butanediimine)Ni(μ−H)]2; deuterium In tetrahydrofuran at -196 - 45℃; under 760.051 Torr; for 24h; Reagent/catalyst; Sealed tube;98%
BUSPIRONE
36505-84-7

BUSPIRONE

C21H21(2)H10N5O2*ClH

C21H21(2)H10N5O2*ClH

Conditions
ConditionsYield
Stage #1: BUSPIRONE With water-d2; lithium carbonate; triisopropylsilanethiol In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation;
Stage #2: With hydrogenchloride In 1-methyl-pyrrolidin-2-one
88%
BUSPIRONE
36505-84-7

BUSPIRONE

A

6'-Hydroxybuspirone
125481-61-0

6'-Hydroxybuspirone

B

6,10-dihydroxybuspirone

6,10-dihydroxybuspirone

Conditions
ConditionsYield
With sodium hexamethyldisilazane; triethyl phosphite In tetrahydrofuran at -60 - 20℃; Large scale;A 71%
B 13 %Chromat.
triethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)silane
745783-97-5

triethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)silane

BUSPIRONE
36505-84-7

BUSPIRONE

8-(4-(4-(4-(triethylsilyl)pyrimidin-2-yl)piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione

8-(4-(4-(4-(triethylsilyl)pyrimidin-2-yl)piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione

Conditions
ConditionsYield
With 1,2-dimethoxyethane; potassium hexamethylsilazane for 3h; Inert atmosphere; regioselective reaction;29%
sodium 7‐azido‐1,1‐difluoroheptane‐1‐sulfinate

sodium 7‐azido‐1,1‐difluoroheptane‐1‐sulfinate

BUSPIRONE
36505-84-7

BUSPIRONE

C28H42F2N8O2
1450912-68-1

C28H42F2N8O2

Conditions
ConditionsYield
With tert.-butylhydroperoxide; toluene-4-sulfonic acid; zinc(II) chloride In water; dimethyl sulfoxide at 50℃; Cooling with ice;9%
2-oxo-2-(4-(prop-2-yn-1-yloxy)phenyl)acetic acid

2-oxo-2-(4-(prop-2-yn-1-yloxy)phenyl)acetic acid

BUSPIRONE
36505-84-7

BUSPIRONE

C31H37N5O4

C31H37N5O4

Conditions
ConditionsYield
With ammonium peroxydisulfate; silver nitrate; trifluoroacetic acid In dichloromethane; water at 60℃; for 3h;9%
BUSPIRONE
36505-84-7

BUSPIRONE

5-Hydroxybuspirone

5-Hydroxybuspirone

Conditions
ConditionsYield
Stage #1: BUSPIRONE With ethylenediaminetetraacetic acid trisodium salt; oxygen; manganese (II) acetate tetrahydrate; ascorbic acid In water pH=4; Udenfriend reaction;
Stage #2: With ferrous(II) sulfate heptahydrate; ethylenediaminetetraacetic acid trisodium salt; oxygen In water at 45℃; for 2h; Udenfriend reaction;
5.16%
BUSPIRONE
36505-84-7

BUSPIRONE

Buspirone N-oxide

Buspirone N-oxide

Conditions
ConditionsYield
With Davis' N-sulfonyloxaziridine In dichloromethane at 25℃; for 1h; Yield given;
BUSPIRONE
36505-84-7

BUSPIRONE

(R)-6'-Hydroxybuspirone

(R)-6'-Hydroxybuspirone

Conditions
ConditionsYield
With Bacillus megaterium cytochrome P450 9-10A-F87A monooxygenase; NADPH In various solvents at 20℃; for 3h; pH=8.2;
BUSPIRONE
36505-84-7

BUSPIRONE

6'-Hydroxybuspirone
125481-61-0

6'-Hydroxybuspirone

Conditions
ConditionsYield
Stage #1: BUSPIRONE With sodium hexamethyldisilazane; triethyl phosphite In tetrahydrofuran at -70 - -10℃; Large scale;
Stage #2: With oxygen In tetrahydrofuran at -37℃; Large scale;
Stage #1: BUSPIRONE With sodium hexamethyldisilazane; triethyl phosphite In tetrahydrofuran at -38 - -33℃;
Stage #2: With oxygen In tetrahydrofuran at -40 - -28℃;
BUSPIRONE
36505-84-7

BUSPIRONE

C21H30N5O2(1-)*K(1+)

C21H30N5O2(1-)*K(1+)

Conditions
ConditionsYield
With potassium hexamethylsilazane In tetrahydrofuran
BUSPIRONE
36505-84-7

BUSPIRONE

C21H31N5O4

C21H31N5O4

Conditions
ConditionsYield
Stage #1: BUSPIRONE In tetrahydrofuran Alkaline conditions;
Stage #2: With oxygen
BUSPIRONE
36505-84-7

BUSPIRONE

C21H21(3)H10N5O2

C21H21(3)H10N5O2

Conditions
ConditionsYield
With tritium oxide In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation;

36505-84-7Relevant articles and documents

Buspirone Analogues. 1. Structure-Activity Relationships in a Series of N-Aryl- and Heteroarylpiperazine Derivatives

Yevich, J. P.,Temple, D. L.,New, J. S.,Taylor, Duncan P.,Riblet, L. A.

, p. 194 - 203 (1983)

A series of analogues of buspirone was synthesized in which modifications were made in the aryl moiety, alkylene chain length, and cyclic imide portion of the molecule.These compounds were tested in vitro for their binding affinities to rat brain membrane sites labeled by either the dopamine antagonist spiperone or the α1-adrenergic antagonist WB-4101.Compounds were also tested in vivo for tranquilizing properties and induction of catalepsy.Potency at the spiperone binding site was affected by alkylene chain length and imide portion composition.Nonortho substituents on the aryl moiety had little effect on spiperone binding affinity.Structure-activity relationships of ortho substituents demonstrated only modest correlations between the receptor binding data and physical parameters of the substituents.The complex nature of the drug-receptor interactions may be understood in terms of the fit of buspirone to a hypothetical model of the dopamine receptor.

Nucleophilic aromatic substitution reactions under aqueous, mild conditions using polymeric additive HPMC

Ansari, Tharique N.,Borlinghaus, Niginia,Braje, Leon H.,Braje, Wilfried M.,Handa, Sachin,Ogulu, Deborah,Wittmann, Valentin

supporting information, p. 3955 - 3962 (2021/06/17)

The use of the inexpensive, benign, and sustainable polymer, hydroxypropyl methylcellulose (HPMC), in water enables nucleophilic aromatic subsitution (SNAr) reactions between various nucleophiles and electrophiles. The mild reaction conditions facilitate a broad functional group tolerance that can be utilized for subsequent derivatization for the synthesis of pharmaceutically relevant building blocks. The use of only equimolar amounts of all reagents and water as reaction solvent reveals the greenness and sustainability of the methodology presented herein.

Large-steric-hindrance N-heterocyclic carbene palladium complex, preparation method and application thereof, and synthesis method of sonidegib based on large-steric-hindrance N-heterocyclic carbene palladium complex

-

Paragraph 0195; 0202-0204, (2021/01/24)

The invention belongs to the technical field of organic synthesis and chemical catalysis, and discloses a large-steric-hindrance N-heterocyclic carbene palladium complex, a preparation method thereof,an application of the complex in efficient catalysis of a C-N coupling reaction under a room-temperature air condition, and a synthesis method of sonidegib based on the complex. According to the large-steric-hindrance N-heterocyclic carbene palladium complex, diphenyl imidazole serves as a main ligand framework, functionalized allyl serves as an auxiliary ligand, the functionalized allyl is introduced beside a metal center of a catalyst to serve as an auxiliary ligand, the catalytic activity and stability are remarkably improved, the large-steric-hindrance N-heterocyclic carbene palladium complex can be applied to efficient catalysis of a CN coupling reaction, particularly, the CN coupling reaction can be efficiently catalyzed under the room temperature condition, and the yield can reachup to 99%. The invention also provides a method for synthesizing sonidegib by taking aryl/aliphatic amine and aryl chloride as reactants and a three-step method at room temperature under the catalysisof a palladium catalytic system, the synthetic method has few steps, and the total yield can reach 74.5%.

Fast continuous alcohol amination employing a hydrogen borrowing protocol

Labes, Ricardo,Mateos, Carlos,Battilocchio, Claudio,Chen, Yiding,Dingwall, Paul,Cumming, Graham R.,Rincón, Juan A.,Nieves-Remacha, Maria José,Ley, Steven V.

supporting information, p. 59 - 63 (2019/01/11)

A continuous flow method for the direct conversion of alcohols to amines via a hydrogen borrowing approach is reported. The method utilises a low loading (0.5%) of a commercial catalyst system ([Ru(p-cymene)Cl2]2 and DPEPhos), reagent grade solvent and is selective for primary alcohols. Successful methylation of amines using methanol and the direct dimethylamination of alcohols using commercial dimethylamine solution are reported. The synthesis of two pharmaceutical agents Piribedil (5) and Buspirone (25) were accomplished in good yields employing these new methods.

The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands

Tandon, Manish,O'Donnell, Mary-Margaret,Porte, Alex,Vensel, David,Yang, Donglai,Palma, Rocio,Beresford, Alan,Ashwell, Mark A.

, p. 1709 - 1712 (2007/10/03)

New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metabolism by human cytochrome P450 (CYP3A4). Modifications to these structures were assessed in silico for their influence on both 5HT 1A affinity and metabolism. Selected new molecules were synthesized and purified in a parallel chemistry approach to determine structure activity relationships (SARs). The resulting molecules were assessed in vitro for their 5HT1A affinity and half-life in a heterologously expressed human CYP3A4 assay. Molecular features responsible for 5-HT1A affinity and CYP3A4 stability are described.

Process for the preparation of high purity buspiron and the hydrochloride thereof

-

, (2008/06/13)

Process for the preparation of 8 -[4 -[4-(pyrimidine-2-yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7,9-dione (buspiron) of the Formula I STR1 and the hydrochlorides thereof having high purity by continuously adding a solution of 8-[4-[4-(pyrimidine-2-yl)-piperazine-1-yl]-but-2 -inyl]-8-aza-spiro[4.5]decane-7,9-dione of the formula II STR2 formed with an inert organic solvent having a concentration of at least 40% by weight to a suspension of a hydrogenation catalyst in an inert organic solvent and optionally converting the 8-[4-[4-(pyrimidine-2-yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7,9-dione thus obtained into the hydrochloride thereof.

PD(O)-CATALYSED SYHTHESIS OF BUSPIRONE AND GEPIRONE

Kuo, David L.

, p. 1463 - 1470 (2007/10/02)

A novel synthetic approach to buspirone and its analogue (gepirone) is described, in which 3 subunits, namely 2-(1-piperazinyl)pyrimidine, a bifunctional allylderivative, and an imide were efficiently assembled via a Pd(O)-catalysed amination-imidation sequence followed by a hydrogenation.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

Ishizumi,Kojima,Antoku

, p. 2288 - 2300 (2007/10/02)

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.

Pharmaceutically useful polymorphic modification of buspirone

-

, (2008/06/13)

Buspirone hydrochloride can exist in two polymorphic forms and the newly discoverd lower melting form, which is thermodynamically favored at pharmaceutically relevant temperatures, offers advantage in manufacture of buspirone pharmaceutical compositions .

Process for buspirone hydrochloride polymorphic crystalline form conversion

-

, (2008/06/13)

A process for conversion of one polymorphic crystalline form of buspirone into its other polymorphic crystalline form.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 36505-84-7